Breast Cancer

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Lisa Newman, MD, MPH, FACS, FASCO, highlights the history and ongoing research of the genotype causing predisposition to TNBC in African-American women.

Jane L. Meisel, MD, an assistant professor, Department of Hematology and Medical Oncology and Department of Gynecology & Obstetrics, Winship Cancer Institute, Emory University School of Medicine, discusses optimizing genomic assays in early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Aditya Bardia, MD, MPH, discusses the recent momentum in metastatic triple-negative breast cancer treatment.

Adding the CDK4/6 inhibitor ribociclib to fulvestrant significantly improved overall survival as a first- or second-line treatment for postmenopausal women with hormone receptor–positive/HER2-negative breast cancer, according to findings from a preplanned interim analysis of the phase III MONALEESA-3 trial.

We traveled to Pasadena, California, for a State of the Science Summit™ on Breast Cancer, which featured insights from the faculty from City of Hope.

Jane Meisel, MD, provides insight on how genomic assays are helping to individualize treatment plans and strategies to determine the optimal duration of endocrine therapy.

Abemaciclib plus fulvestrant improved overall survival in patients with hormone receptor–positive, HER2-negative breast cancer.

Pembrolizumab in combination with chemotherapy led to a statistically significant improvement in pathological complete response rates compared with placebo plus chemotherapy in the neoadjuvant phase of a neoadjuvant/adjuvant treatment regimen in patients with triple-negative breast cancer, meeting one of the dual primary endpoints of the phase III KEYNOTE-522 trial.

During a recent OncLive Peer Exchange®, a panel of breast cancer experts discussed how they are using CDK4/6 inhibitors in their practices. They shared their insights on the tolerability and toxicity profiles of the FDA-approved CDK4/6 inhibitors, how they choose which agents to use for each patient, and how they select the next line of therapy after the patient progresses.